NCT07069647Recruiting
Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics
Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics: A Randomized Controlled Clinical Trial
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are leading causes of vision loss, with rising incidence due to aging populations and increasing diabetes prevalence. However, delayed diagnoses are common due to low disease literacy and lack of dedicated screening tools in internal medicine. This multi-center RCT at National Taiwan University Hospital evaluates the clinical effectiveness and cost-effectiveness of the VeriSee AI-assisted diagnostic software for DR and AMD screening. Participants include adults with diabetes and individuals aged 50 and above meeting AMD screening criteria, randomized to AI-assisted screening with immediate physician explanation or standard physician-only screening. Primary outcomes include detection rates of DR and AMD, ophthalmology referral outcomes, and patient/physician satisfaction. Data collection will occur from April 2025 to December 2027. This study aims to provide evidence on the clinical utility of AI-assisted ophthalmic screening in improving early detection, facilitating timely treatment, and reducing severe visual impairment and healthcare burdens in real-world clinical settings.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 4300 (estimated)
- First submitted
- 14 Jul 2025
- Start date
- 2 Oct 2025
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- National Taiwan University Hospital
- Diseases
- Macular degeneration, Diabetic eye disease
- NCT number
- NCT07069647
What you commit to
- Study type: Interventional
- Planned participants: 4300
- From 2 Oct 2025 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- The patient does not agree to participate in the trial or is unable to provide informed consent.
Who the study is looking for
- VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
- VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Taiwan University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.